Press Releases

 
Press Releases
  Date Title and Summary View
Apr 20, 2017
HERTFORDSHIRE, England and PITTSBURGH, April 20, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL), today announced the U.S. launch of Perphenazine Tablets USP, 2 mg, 4 mg, 8 mg and 16 mg, a generic version of the reference listed drug, Trilafon Tablets 2 mg, 4 mg, 8 mg and 16 mg, originally marketed by Schering. Mylan received final approval fro...
Mar 31, 2017
HERTFORDSHIRE, England and PITTSBURGH, March 31, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that Meridian Medical Technologies, a Pfizer company and Mylan's manufacturing partner for EpiPen® Auto-Injector, has expanded a voluntary recall of select lots of EpiPen (epinephrine injection, USP) and EpiPen Jr® (epineph...
Mar 29, 2017
HERTFORDSHIRE, England and PITTSBURGH, March 29, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL), today announced the successful acquisition of the global rights to the Cold-EEZE® brand cold remedy line from ProPhase Labs, Inc. The transaction provides Mylan all assets and rights relating ...
Mar 29, 2017
HERTFORDSHIRE, England and PITTSBURGH, March 29, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today commented on the status of its abbreviated new drug application (ANDA) with the U.S. Food and Drug Administration (FDA) for its generic version of GlaxoSmithKline's Advair Diskus®. In conjunction with Mylan's GDUFA goal date, t...
Mar 28, 2017
HERTFORDSHIRE, England and PITTSBURGH, March 28, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the appointment of Daniel M. Gallagher as chief legal officer. He will be joining the company on April 17, 2017. Gallagher joins Mylan from Patomak Global Partners, a consulting firm...
Mar 20, 2017
HERTFORDSHIRE, England and PITTSBURGH, March 20, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL), a leading global pharmaceutical company, today announced receipt of tentative approval from the U.S. Food and Drug Administration under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application for Efavirenz, Lamivud...
Mar 13, 2017
HERTFORDSHIRE, England and PITTSBURGH, March 13, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL), today announced the U.S. launch of Exemestane Tablets, 25 mg, a generic version of the reference listed drug, Pfizer's Aromasin® Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Dr...
Mar 13, 2017
HERTFORDSHIRE, England and PITTSBURGH, March 13, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that Mylan has agreed to the terms of a global settlement with Genentech, Inc. and F. Hoffmann-La Roche Ltd. in relation to patents for Herceptin® (trastuzumab), which provides Mylan with global licenses for its trastuzumab prod...
Mar 10, 2017
HERTFORDSHIRE, England and PITTSBURGH, March 10, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that the company will present at the Barclays Global Healthcare Conference on Tuesday, March 14, 2017, in Miami. The presentation is scheduled to begin at 9:30 a.m. ET. Interested p...
Mar 10, 2017
HERTFORDSHIRE, England and PITTSBURGH, March 10, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL), today announced the U.S. launch of Desvenlafaxine Extended-release Tablets, 50 mg and 100 mg, a generic version of Pfizer's Pristiq® Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated Ne...
Page:
1
... NextLast
= add release to Briefcase